Korro Bio, Inc. (KRRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Korro Bio, Inc. on March 27, 2025. The filing addresses Item 5.02 regarding the departure of certain officers and the appointment of new officers effective March 27, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Resumption of CFO Duties: Vineet Agarwal ended his temporary medical leave of absence (which began February 11, 2025) and was reappointed as Chief Financial Officer and principal financial officer.
- Interim CFO Transition: Dr. Ram Aiyar ceased serving as interim principal financial officer but continues as President and Chief Executive Officer.
- Appointment of Principal Accounting Officer: Oliver Dolan, currently Senior Vice President, Finance, was appointed as principal accounting officer. He had served in this role on an interim basis since February 11, 2025.
Guidance, Outlook, and Compensation
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. Regarding compensation:
- Mr. Agarwal will not receive additional compensation for his reappointment.
- Mr. Dolan was granted a stock option award to purchase 20,000 shares of common stock. The exercise price equals the closing price on the grant date, with the grant effective April 1, 2025.
- Mr. Dolan entered into the Company's standard indemnification agreement.
Key Facts for Investor Verification
- Confirm the stability of the finance leadership team following the return of the permanent CFO.
- Verify the terms of the 20,000-share stock option grant to Mr. Dolan in future equity filings.
- Note that no financial results or operational updates were disclosed in this specific report.